Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Nephrology
You have accessRestricted Access

Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results

Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, Borislav D. Dimitrov, Dick de Zeeuw, Darcy A. Hille, Shahnaz Shahinfar, George W. Carides, Barry M. Brenner and ; for the RENAAL Study Group
JASN December 2004, 15 (12) 3117-3125; DOI: https://doi.org/10.1097/01.ASN.0000146423.71226.0C
Giuseppe Remuzzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piero Ruggenenti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annalisa Perna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Borislav D. Dimitrov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dick de Zeeuw
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darcy A. Hille
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahnaz Shahinfar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George W. Carides
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry M. Brenner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Information

vol. 15 no. 12 3117-3125
DOI 
https://doi.org/10.1097/01.ASN.0000146423.71226.0C
PubMed 
15579515

Published By 
American Society of Nephrology
Print ISSN 
1046-6673
Online ISSN 
1533-3450
History 
  • Received for publication April 8, 2004
  • Accepted for publication September 12, 2004
  • Published online December 3, 2004.

Copyright & Usage 
© 2004 American Society of Nephrology

Author Information

  1. Giuseppe Remuzzi*†,
  2. Piero Ruggenenti*†,
  3. Annalisa Perna*,
  4. Borislav D. Dimitrov*,
  5. Dick de Zeeuw‡,
  6. Darcy A. Hille§,
  7. Shahnaz Shahinfar§,
  8. George W. Carides§,
  9. Barry M. Brenner∥ and
  10. for the RENAAL Study Group
  1. *Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” Villa Camozzi, Ranica, and †Unit of Nephrology, Ospedali Riuniti, Azienda Ospedaliera, Bergamo, Italy; ‡University of Groningen, Groningen, The Netherlands; § Merck Research Laboratories, Blue Bell, Pennsylvania; and ∥Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts
  1. Correspondence to Dr. Piero Ruggenenti, Clinical Research Center for Rare Diseases “Aldo e Cele Daccò,” “Mario Negri” Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. Phone: +39-035-319-888; Fax: +39-035-319-331; E-mail: manuelap{at}marionegri.it
View Abstract

Statistics from Altmetric.com

Article usage

Article usage: December 2004 to December 2020

AbstractFullPdf
Dec 2004411676331
Jan 200513230376
Feb 20058626166
Mar 20054318243
Apr 20053313532
May 20054514037
Jun 20053810514
Jul 2005207833
Aug 2005288140
Sep 2005248446
Oct 2005256419
Nov 20052711224
Dec 2005116782
Jan 2006196969
Feb 2006187991
Mar 20062310081
Apr 2006119364
May 20062510393
Jun 2006178993
Jul 200694348
Aug 2006193644
Sep 2006153736
Oct 2006155750
Nov 2006215058
Dec 2006115636
Jan 2007173437
Feb 2007113430
Mar 200755638
Apr 2007115840
May 2007225464
Jun 2007144538
Jul 2007144431
Aug 2007184627
Sep 2007182742
Oct 2007184351
Nov 2007143329
Dec 200762419
Jan 2008133017
Feb 2008153038
Mar 2008122321
Apr 2008173341
May 2008132621
Jun 2008212915
Jul 2008142229
Aug 2008143718
Sep 2008143324
Oct 2008112626
Nov 200894223
Dec 2008102913
Jan 2009112915
Feb 2009113321
Mar 2009143729
Apr 2009122222
May 2009141315
Jun 200983326
Jul 2009111911
Aug 200972727
Sep 200972425
Oct 2009101817
Nov 2009112621
Dec 2009122323
Jan 201051812
Feb 201052215
Mar 2010101714
Apr 201062920
May 201072433
Jun 201052017
Jul 201062520
Aug 201062425
Sep 201031418
Oct 201062923
Nov 2010172522
Dec 2010231413
Jan 2011221813
Feb 2011311717
Mar 2011243919
Apr 201120913
May 2011151724
Jun 2011151919
Jul 2011211923
Aug 2011252225
Sep 2011192626
Oct 2011161718
Nov 2011281820
Dec 2011251214
Jan 2012231522
Feb 2012122221
Mar 2012121117
Apr 2012281822
May 2012101719
Jun 2012201225
Jul 2012141614
Aug 2012211319
Sep 2012141223
Oct 2012381722
Nov 2012252124
Dec 2012271516
Jan 2013334528
Feb 2013151926
Mar 201334917
Apr 2013452439
May 2013382334
Jun 2013102720
Jul 20131098
Aug 201316613
Sep 2013332221
Oct 2013171818
Nov 2013151519
Dec 20139129
Jan 2014112424
Feb 2014251514
Mar 2014122227
Apr 201416815
May 201491418
Jun 2014111119
Jul 201412129
Aug 2014171416
Sep 2014181520
Oct 2014121711
Nov 201481919
Dec 201471013
Jan 2015169613
Feb 2015716214
Mar 20152812111
Apr 201522566
May 201586310
Jun 2015176812
Jul 20151268
Aug 20157146
Sep 20157118
Oct 201512125
Nov 20158119
Dec 2015171636
Jan 2016161522
Feb 201681019
Mar 2016301222
Apr 2016172222
May 201624147
Jun 2016241323
Jul 2016291218
Aug 2016181115
Sep 201618109
Oct 201621168
Nov 2016281612
Dec 201618144
Jan 201720219
Feb 2017182016
Mar 2017141713
Apr 2017162218
May 2017171720
Jun 201723710
Jul 2017171612
Aug 2017171112
Sep 2017181415
Oct 20172519130
Nov 2017171314
Dec 20171499
Jan 201891911
Feb 201881916
Mar 201891710
Apr 20189108
May 20181778
Jun 2018994
Jul 2018111716
Aug 20181895
Sep 201861716
Oct 201823020
Nov 201832516
Dec 201803214
Jan 201922621
Feb 201971522
Mar 201923621
Apr 201953519
May 201932521
Jun 201972215
Jul 201942729
Aug 201934013
Sep 2019146318
Oct 20194255
Nov 201983418
Dec 201932111
Jan 202022214
Feb 202042515
Mar 202022714
Apr 202072717
May 202083119
Jun 202012616
Jul 20203329
Aug 20205139
Sep 202072825
Oct 202092214
Nov 20206329
Dec 20205328

Cited By...

  • 77 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 15 (12)
Journal of the American Society of Nephrology
Vol. 15, Issue 12
1 Dec 2004
  • Table of Contents
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results
Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, Borislav D. Dimitrov, Dick de Zeeuw, Darcy A. Hille, Shahnaz Shahinfar, George W. Carides, Barry M. Brenner
JASN Dec 2004, 15 (12) 3117-3125; DOI: 10.1097/01.ASN.0000146423.71226.0C

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results
Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, Borislav D. Dimitrov, Dick de Zeeuw, Darcy A. Hille, Shahnaz Shahinfar, George W. Carides, Barry M. Brenner
JASN Dec 2004, 15 (12) 3117-3125; DOI: 10.1097/01.ASN.0000146423.71226.0C
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy
  • Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors
  • IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria
Show more Clinical Nephrology

Cited By...

  • Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study
  • Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction
  • Mechanisms and Treatment of CKD
  • Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence
  • Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study
  • Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study
  • Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy
  • Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
  • Rosiglitazone Improves Glomerular Hyperfiltration, Renal Endothelial Dysfunction, and Microalbuminuria of Incipient Diabetic Nephropathy in Patients
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire